Andrew Murray, DO
Interventional Cardiology · Venice, FLNPI 1356788624
Payments from drug & device makers
Across 210 payments — averaging $63.31 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Angiodynamics, Inc.$4K
- Abbott$2K
- Edwards Lifesciences$1K
- Medtronic$1K
- Boston Scientific$925
- AstraZeneca$461
- plus $4K from 30 others
What the payments were for
- Travel & lodging$2,97022%
- Food & beverage$6,24147%
- Education$4,08531%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Angiodynamics, Inc. | 1 | $4,028 |
| Abbott | 21 | $1,817 |
| Edwards Lifesciences | 12 | $1,265 |
| Medtronic(2 entities) | 11 | $1,215 |
| Boston Scientific | 17 | $925 |
| AstraZeneca | 14 | $461 |
| ZOLL Services LLC (a/k/a ZOLL Lifecor Corp) | 13 | $453 |
| Amgen | 19 | $384 |
| Johnson & Johnson | 17 | $376 |
| Cardiovascular Systems Inc. | 20 | $301 |
| Abiomed | 5 | $274 |
| Sanofi-aventis U.S. LLC | 4 | $185 |
| Silk Road Medical, Inc. | 1 | $155 |
| Inari Medical, Inc. | 1 | $153 |
| Teleflex LLC | 1 | $128 |
| Merck | 6 | $123 |
| Kestra Medical Technology Services, Inc. | 5 | $122 |
| Novartis | 8 | $121 |
| Boehringer Ingelheim | 3 | $99 |
| E.r. Squibb & Sons, L.L.C. | 5 | $92 |
| Alnylam Pharmaceuticals Inc. | 3 | $62 |
| Verge Medical, Inc. | 1 | $62 |
| Cardiva Medical, Inc. | 1 | $60 |
| Philips North America LLC | 3 | $60 |
| Penumbra, Inc. | 2 | $56 |
| Pfizer | 3 | $51 |
| Bayer | 2 | $44 |
| Lexicon Pharmaceuticals, Inc. | 2 | $42 |
| Shockwave Medical, Inc | 1 | $35 |
| Lantheus Medical Imaging, Inc. | 1 | $32 |
| Esperion Therapeutics, Inc. | 2 | $32 |
| Irhythm Technologies, Inc. | 1 | $20 |
| Astellas Pharma US Inc | 1 | $18 |
| W. L. Gore & Associates, Inc. | 1 | $16 |
| ZOLL Circulation Inc | 1 | $15 |
| G Medical Diagnostic Services, Inc. | 1 | $12 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- Auryon$4,028
- Mitra Clip system$1,121
- COUGAR$801
- ENROUTE Transcarotid Neuroprotection System$155
- ENROUTE Transcarotid Stent$155
- FLOWTRIEVER CATHETER, S$153
- CT THROMBECTOMY SYSTEM KIT$153
- WATCHMAN Access System$145
- GUIDELINER$128
- WATCHMAN FLX$121
- GENERAL - STRUCTURAL HEART$117
- XARELTO$117
- GENERAL - THERAPIES$116
- TAGRISSO$109
- DISEASE STATE$107
- LifeVest$106
How this compares
$13,296 in reported general payments places this provider in the 55th percentile of 623 interventional cardiology providers in Florida.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| EntrestoSacubitril/Valsartan | 66 | $45,975 |
| EliquisApixaban | 45 | $33,593 |
| JardianceEmpagliflozin | 23 | $28,139 |
| Repatha SureclickEvolocumab | 23 | $21,004 |
| BrilintaTicagrelor | 20 | $9,759 |
| Metoprolol Succinate | 92 | $1,669 |
| Atorvastatin Calcium | 70 | $1,347 |
| Rosuvastatin Calcium | 34 | $1,227 |
| Ranolazine ErRanolazine | 13 | $1,148 |
| Chlorthalidone | 35 | $995 |
| Amiodarone Hcl | 19 | $881 |
| Isosorbide Mononitrate ErIsosorbide Mononitrate | 55 | $720 |
| Losartan Potassium | 48 | $663 |
| Bumetanide | 14 | $475 |
| Amlodipine Besylate | 45 | $449 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| NovartisEntresto | $121 | $45,97566 claims |
| PfizerEliquis | $51 | $33,59345 claims |
| Boehringer IngelheimJardiance | $99 | $28,13923 claims |
| AstraZenecaBrilinta | $461 | $9,75920 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 55th percentile of 623 interventional cardiology providers in Florida.
Other interventional cardiology in Venice
- Dominick AngiolilloJacksonville$4M
- Douglas SpriggsClearwater$3.2M
- Rakesh PrashadOcala$3.1M
- Aldo Martinez FleitesMiami Lakes$2.2M
- Rohit AminPensacola$2M
- Roberto CubedduNaples$2M
- Arthur LeeGainesville$2M
- Ruby SatpathyJacksonville$1.8M
- Santhosh MathewsBradenton$1.7M
- Pedro Martinez-ClarkMiami$1.7M
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.